<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-TAM21337-MTD-X1-FP0"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 S259 IS: Safe and Affordable Drugs from Canada Act of 2021</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2021-02-04</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>117th CONGRESS</congress><session>1st Session</session><legis-num>S. 259</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20210204">February 4, 2021</action-date><action-desc><sponsor name-id="S311">Ms. Klobuchar</sponsor> (for herself, <cosponsor name-id="S153">Mr. Grassley</cosponsor>, <cosponsor name-id="S354">Ms. Baldwin</cosponsor>, <cosponsor name-id="S252">Ms. Collins</cosponsor>, <cosponsor name-id="S307">Mr. Brown</cosponsor>, <cosponsor name-id="S388">Ms. Hassan</cosponsor>, <cosponsor name-id="S363">Mr. King</cosponsor>, <cosponsor name-id="S057">Mr. Leahy</cosponsor>, <cosponsor name-id="S322">Mr. Merkley</cosponsor>, <cosponsor name-id="S324">Mrs. Shaheen</cosponsor>, <cosponsor name-id="S316">Mr. Whitehouse</cosponsor>, and <cosponsor name-id="S247">Mr. Wyden</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To amend the Federal Food, Drug, and Cosmetic Act to allow for the personal importation of safe and affordable drugs from approved pharmacies in Canada.</official-title></form><legis-body display-enacting-clause="yes-display-enacting-clause"><section section-type="section-one" id="S1"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Safe and Affordable Drugs from Canada Act of 2021</short-title></quote>.</text></section><section id="idD62F459942DF49B59FB3157554963F65"><enum>2.</enum><header>Safe and affordable drugs from Canada</header><text display-inline="no-display-inline">Chapter VIII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/381">21 U.S.C. 381</external-xref> et seq.) is amended by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="idf48230954e2043029ec94f5f5f54478e"><section id="id189b738c0cac476a9d2d54663246c60e"><enum>810.</enum><header>Importation by individuals of prescription drugs from Canada</header><subsection id="id33ce38dcf8e7430ab08fec11acfca021"><enum>(a)</enum><header>In general</header><text>Notwithstanding any other provision of this Act, not later than 180 days after the date of enactment of this section, the Secretary shall promulgate regulations permitting individuals to safely import into the United States a prescription drug described in subsection (b).</text></subsection><subsection id="idF66486A9E01547EE9E748A42F77BF847"><enum>(b)</enum><header>Prescription drug</header><text>A prescription drug described in this subsection—</text><paragraph id="id0DC9EA87C05B4E468E7FF626467560AA"><enum>(1)</enum><text>is a prescription drug that—</text><subparagraph id="id96bd01ac2b9145279c287e30d10bfeb4"><enum>(A)</enum><text>is purchased from an approved Canadian pharmacy;</text></subparagraph><subparagraph id="idc29c4e47bbc4452da50ce5d837551c60"><enum>(B)</enum><text>is dispensed by a pharmacist licensed to practice pharmacy and dispense prescription drugs in Canada;</text></subparagraph><subparagraph id="idabb20122b0304ef2a37dad95b70dd0c5"><enum>(C)</enum><text>is purchased for personal use by the individual, not for resale, in quantities that do not exceed a 90-day supply;</text></subparagraph><subparagraph id="id23541c8a98fe4aa7973afcc757b388bc"><enum>(D)</enum><text>is filled using a valid prescription issued by a physician licensed to practice in a State in the United States; and</text></subparagraph><subparagraph id="id6f615d8cdb584ac29ee7f68d4143928a"><enum>(E)</enum><text>has the same active ingredient or ingredients, route of administration, dosage form, and strength as a prescription drug approved by the Secretary under chapter V; and</text></subparagraph></paragraph><paragraph id="id080b371792344874bb271bf276133a32"><enum>(2)</enum><text>does not include—</text><subparagraph id="ida9f34eddf4b54d208f938b7c47dc8f6e"><enum>(A)</enum><text>a controlled substance (as defined in section 102 of the Controlled Substances Act);</text></subparagraph><subparagraph id="idadf8273e252448429a1eae7cd2aa5671"><enum>(B)</enum><text>a biological product (as defined in section 351 of the Public Health Service Act);</text></subparagraph><subparagraph id="id75570dda7f234c3e829b438b0d566821"><enum>(C)</enum><text>an infused drug (including a peritoneal dialysis solution);</text></subparagraph><subparagraph id="ideabf91f7f74841f786682f63ae3721a2"><enum>(D)</enum><text>an intravenously injected drug;</text></subparagraph><subparagraph id="ide7a9734353324f6d8331e683e162a9db"><enum>(E)</enum><text>a drug that is inhaled during surgery;</text></subparagraph><subparagraph id="id648905d845a74e54bcfaa93e242bd1fd"><enum>(F)</enum><text>a parenteral drug;</text></subparagraph><subparagraph id="id3c0f78d0181443d4a7c2a8c160ea3905"><enum>(G)</enum><text>a drug manufactured through one or more biotechnology processes, including—</text><clause id="id54eab55e3cfb46a0a96c165f8d97719f"><enum>(i)</enum><text>a therapeutic DNA plasmid product;</text></clause><clause id="id0fc9db23d6d247d8926d79d5991989dd"><enum>(ii)</enum><text>a therapeutic synthetic peptide product of not more than 40 amino acids;</text></clause><clause id="id5ca1aa42aa364b6f9d7609cf101019b7"><enum>(iii)</enum><text>a monoclonal antibody product for in vivo use; and</text></clause><clause id="idc7ea61bbb38647f5819f57baef263b33"><enum>(iv)</enum><text>a therapeutic recombinant DNA-derived product;</text></clause></subparagraph><subparagraph id="id6cb89c156cd1434ea22d4bd19b1bb459"><enum>(H)</enum><text>a drug required to be refrigerated at any time during manufacturing, packing, processing, or holding; or</text></subparagraph><subparagraph id="id65f996a1442641a18a8af89e1a289d91"><enum>(I)</enum><text>a photoreactive drug.</text></subparagraph></paragraph></subsection><subsection id="iddc557636ff9d466993f81250425c7b2f"><enum>(c)</enum><header>Approved Canadian pharmacy</header><paragraph id="ida5d18d015b99429f8db4ecf097c7852b"><enum>(1)</enum><header>In general</header><text>In this section, an approved Canadian pharmacy is a pharmacy that—</text><subparagraph id="id477e7f1dca184031aaab95902cdf388c"><enum>(A)</enum><text>is located in Canada; and</text></subparagraph><subparagraph id="ideb55d3b98ae042269e76f70a4fe19b76"><enum>(B)</enum><text>the Secretary certifies—</text><clause id="id2053d0aed50d4ee2ae8cc0d1f1a4260f"><enum>(i)</enum><text>is licensed to operate and dispense prescription drugs to individuals in Canada; and</text></clause><clause id="id093e331404fc442c91be4d484be185a2"><enum>(ii)</enum><text>meets the criteria under paragraph (3).</text></clause></subparagraph></paragraph><paragraph id="id9d7eb12c74494581b465e723c69ed10e"><enum>(2)</enum><header>Publication of approved Canadian pharmacies</header><text>The Secretary shall publish on the internet website of the Food and Drug Administration a list of approved Canadian pharmacies, including the internet website address of each such approved Canadian pharmacy, from which individuals may purchase prescription drugs in accordance with subsection (a).</text></paragraph><paragraph id="id85cfc85f021c435bb406ff4e5bb7e09a"><enum>(3)</enum><header>Additional criteria</header><text>To be an approved Canadian pharmacy, the Secretary shall certify that the pharmacy—</text><subparagraph id="id12acaa80c34c42969e9110ea830613c7"><enum>(A)</enum><text>has been in existence for a period of at least 5 years preceding the date of such certification and has a purpose other than to participate in the program established under this section;</text></subparagraph><subparagraph id="id6b391c716b7c4fffb90d41c3ca5eceea"><enum>(B)</enum><text>operates in accordance with pharmacy standards set forth by the provincial pharmacy rules and regulations enacted in Canada;</text></subparagraph><subparagraph id="id40e4c0202582445fbf5a33090e287cd1"><enum>(C)</enum><text>has processes established by the pharmacy, or participates in another established process, to certify that the physical premises and data reporting procedures and licenses are in compliance with all applicable laws and regulations, and has implemented policies designed to monitor ongoing compliance with such laws and regulations;</text></subparagraph><subparagraph id="id9271d3f4ea46470ca6102c60ea557726"><enum>(D)</enum><text>conducts or commits to participate in ongoing and comprehensive quality assurance programs and implements such quality assurance measures, including blind testing, to ensure the veracity and reliability of the findings of the quality assurance program;</text></subparagraph><subparagraph id="id571531bf23a448df990976daabd442cd"><enum>(E)</enum><text>agrees that laboratories approved by the Secretary shall be used to conduct product testing to determine the safety and efficacy of sample pharmaceutical products;</text></subparagraph><subparagraph id="idce04c7fb8cb34db8b46644264aae86c6"><enum>(F)</enum><text>has established, or will establish or participate in, a process for resolving grievances and will be held accountable for violations of established guidelines and rules;</text></subparagraph><subparagraph id="idbe2ef902f3af4333aba0839dea081669"><enum>(G)</enum><text>does not resell products from online pharmacies located outside Canada to customers in the United States; and</text></subparagraph><subparagraph id="id5e4c0a7901a346678603690f162f854e"><enum>(H)</enum><text>meets any other criteria established by the Secretary.</text></subparagraph></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body></bill> 

